Endovia Health Sciences, Inc. filed a Form S-1 registration statement with the SEC on October 27, 2026, covering the potential resale of up to 1,013,041 shares of common stock by selling stockholder C/M Capital Master Fund, LP under an equity line of credit arrangement.

Key Highlights

  • Shares Registered: Up to 1,013,041 shares of common stock, par value $0.001 per share, are being registered for resale by C/M Capital Master Fund, LP.
  • Potential Gross Proceeds to Company: Endovia may receive up to $29,800,324 in aggregate gross proceeds from sales to the selling stockholder under the Purchase Agreement, representing the total maximum amount less prior sales.
  • Recent Share Price: The last reported sale price of common stock on NYSE American was $0.1493 per share on October 22, 2026.
  • Purchase Agreement Date: The Securities Purchase Agreement establishing the equity line of credit is dated September 19, 2025.
  • Reverse Stock Split: All share and per share figures in the prospectus reflect a one-for-four reverse stock split that took effect July 24, 2026 at 4:30 pm ET.
  • Company Classification: Endovia is identified in the filing as a non-accelerated filer and a smaller reporting company.

Endovia Seeks to Register ELOC Shares for C/M Capital Resale

According to the filing, the prospectus relates to the potential resale, from time to time, by C/M Capital Master Fund, LP of up to 1,013,041 shares of Endovia Health Sciences common stock. These shares consist of "Purchase Shares" that the company may elect, in its sole discretion and subject to the restrictions and satisfaction of conditions in the Purchase Agreement, to issue and sell to the selling stockholder. The company disclosed that its common stock is traded on NYSE American:EDVA.

The filing states that Endovia itself is not selling any securities under this prospectus and will not receive any proceeds from the selling stockholder's resale of shares on the open market. However, the company noted it may receive up to $29,800,324 in aggregate gross proceeds from its own sales of shares to C/M Capital under the Purchase Agreement. The filing cautions that "the actual proceeds from the Selling Stockholder may be less than this amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold."

The filing notes that the selling stockholder may sell shares on NYSE American or through private transactions at prevailing market prices or negotiated prices. Endovia disclosed it will bear all registration costs, including compliance with state securities laws, while the selling stockholder will bear any commissions or markdowns. The filing also identifies the selling stockholder as "an underwriter under the Securities Act of 1933 with respect to the resale of shares sold by it on the NYSE American." The prospectus is preliminary and subject to completion; the registration statement had not yet been declared effective as of the filing date.

What Was Disclosed

Endovia Health Sciences filed a preliminary S-1 registration statement on October 27, 2026, to register up to 1,013,041 shares of common stock for resale by C/M Capital Master Fund, LP under a September 19, 2025 equity line of credit agreement, with potential company proceeds of up to $29,800,324.